I put in a request to the site Admins if they coul
Post# of 148190
Lantheus Holdings Inc which completed their acquisition of Progenix in June 2020. I think there may be some market synergy between the two when Leronlimab sales royalties start flowing their direction.
I've seen some mentions on this board along the same lines of thinking.
LNTH closed 8/7/2020 @ $13.29 P/E: 43.40
Currently under all moving averages. Decent pricing right now.
Certainly more potential bang for your buck with CYDY, but the revenue influx to LNTH could help fund their own organic products, or they might do share buybacks to go private....both causing share price to go up.